NEW YORK (GenomeWeb News) – Rosetta Genomics said today that the New York State Department of Health has given the company's miRview lung assay final approval for marketing in the state.

As a result, the company can offer the microRNA-based test for the differentiation of the four main subtypes of lung cancer in all 50 states. New York had given the test, launched in July 2011, conditional approval in June.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.